文献速递头颈部肿瘤放疗

头颈部淋巴上皮瘤样癌的临床特征、预后因素与治疗方式:华南地区真实世界研究

Clinical characteristics, prognostic factors, and treatment modalities for head and neck lymphoepithelioma-like carcinoma: A real-world study from southern China.
PubMed 文献 · Radiother Oncol · 2023-07-20

本研究回顾性纳入2001年12月至2021年3月华南地区连续初诊非转移性头颈部淋巴上皮瘤样癌(HNLELC)根治性治疗患者288例,分析临床特征、预后因素与治疗方式。EBER阳性率94.8%(239/252),颈部淋巴结侵犯率52.8%(152/288),3年总生存率89.4%。根治性放疗与术后放疗(SRT)各项3年生存结局相当(均P>0.05),EBER状态是总生存的独立有利预后因素(HR=0.356,95%CI:0.144-0.882,P=0.026)。

要点

  • EBER阳性率94.8%(239/252),颈部淋巴结侵犯率52.8%(152/288),提示HNLELC与EBV感染及颈部淋巴结侵犯相关。
  • 单纯手术较SRT的3年局部无复发生存率更低(92.8% vs 96.5%,P=0.012)、区域无复发生存率更低(89.3% vs 96.8%,P=0.002)。
  • 根治性放疗与SRT各项3年生存结局相当(均P>0.05),作者认为前者可作为不适合或不愿手术患者的良好替代。

核心结论

  • HNLELC与EBV感染及颈部淋巴结侵犯相关。
  • 根治性放疗与SRT的生存结局相似,作者认为其可作为不适合或不愿手术患者的良好替代。

研究设计与样本

  • 回顾性纳入2001年12月至2021年3月华南地区连续初诊非转移性HNLELC并接受根治性治疗的患者,共288例。
  • 其中单纯根治性手术87例(30.2%),根治性放疗±同步化疗43例(14.9%),手术+术后放疗(SRT)158例(54.9%)。

主要发现

  • EBER阳性率为94.8%(239/252),颈部淋巴结侵犯率为52.8%(152/288)。
  • T1-2与T3-4分期间的淋巴结转移率无显著差异(49.5% vs 56.5%,P=0.308)。
  • 3年总生存率、无病生存率、局部区域无复发生存率、无远处转移生存率分别为89.4%、78.7%、89.2%、87.7%。
  • 与SRT相比,单纯手术与3年局部无复发生存率降低相关(92.8% vs 96.5%,P=0.012),并与3年区域无复发生存率降低相关(89.3% vs 96.8%,P=0.002)。
  • 根治性放疗与SRT在所有3年生存结局上结果相当(均P>0.05)。

关键数值与推荐

  • 多因素分析显示EBER状态是总生存的独立有利预后因素(HR=0.356,95%CI:0.144-0.882,P=0.026)。
  • 作者认为根治性放疗可作为不适合或不愿手术患者的良好替代。

临床怎么用

  • 作者认为根治性放疗可作为不适合或不愿手术的HNLELC患者的良好替代。
  • 原文未据此给出其他推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We aimed to elucidate the clinical characteristics, prognostic factors and optimal treatment modalities of head and neck lymphoepithelioma-like carcinoma (HNLELC). METHODS: Consecutive patients newly-diagnosed with non-metastatic HNLELC between December 2001 and March 2021 treated with curative intent were retrospectively reviewed. RESULTS: A total of 288 patients were included, of whom 87 (30.2%) underwent radical surgery alone, 43 (14.9%) underwent definitive radiotherapy with or without concurrent chemotherapy, and 158 (54.9%) underwent surgery followed by postoperative radiotherapy (SRT). Epstein-Barr virus-encoded small RNA (EBER) was positive in 94.8% (239/252) of patients. Cervical node infiltration was seen in 52.8% (152/288) of patients. No significant difference was found in nodal metastasis rate between T1-2 and T3-4 classifications (49.5% vs. 56.5%, p = 0.308). The 3-year overall survival (OS), disease-free survival, locoregional relapse-free survival, and distant metastasis-free survival rates were 89.4%, 78.7%, 89.2%, and 87.7%, respectively. Compared to SRT, surgery alone associated with significant reduced 3-year local (92.8% vs. 96.5%, p = 0.012) and regional relapse-free survival rates (89.3% vs. 96.8%, p = 0.002). Definitive radiotherapy and SRT demonstrated comparable results in all 3-year survival outcomes (all p>0.05). Multivariate analysis found EBER status was an independent favorable prognostic factor for OS (HR = 0.356, 95% CI: 0.144-0.882, p = 0.026). CONCLUSION: HNLELC was observed to associate with EBV infection and cervical nodal infiltration. Definitive radiotherapy achieved similar survival outcomes compared to SRT, and may serve as a good substitute for patients unfit or unwilling to undergo surgery.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Liu ZQ, Feng YF, Xiao Y, et al. Clinical characteristics, prognostic factors, and treatment modalities for head and neck lymphoepithelioma-like carcinoma: A real-world study from southern China. Radiother Oncol. 2023. PMID: 37480992. doi:10.1016/j.radonc.2023.109814

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。